Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius PharmaceuticalsCTXR +6.28%25 Gross Margin % is 80.26% as of Mar. 2026. GuruFocus rates CTXR with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 734 Biotechnology companies, Citius Pharmaceuticals ranks better than 73.02% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Citius Pharmaceuticals had a gross margin of 80.26% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Citius Pharmaceuticals Gross Margin % Related Terms
Citius Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Citius Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTXR vs LEXX, HIND, PTN: Gross Margin % Comparison
For the Biotechnology subindustry, Citius Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Citius Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Citius Pharmaceuticals (CTXR) has a Gross Margin % of 80.26% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Citius Pharmaceuticals and its competitors. According to the industry distribution chart, Citius Pharmaceuticals ranks #198 out of 734 companies in the Biotechnology industry, placing it in the top 27%.
Is Citius Pharmaceuticals' Gross Margin % too high?
Citius Pharmaceuticals' current Gross Margin % is 80.26%. The Biotechnology industry median Gross Margin % is 60.69. Citius Pharmaceuticals' value of 80.26% is 32.2% above this industry median. Based on the distribution chart, Citius Pharmaceuticals ranks #198 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Gross Margin % compare to LEXX and HIND?
According to the Biotechnology industry distribution chart, Citius Pharmaceuticals ranks #198 out of 734 companies for Gross Margin %. This puts Citius Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 60.69. Citius Pharmaceuticals' value of 80.26% is 32.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.69, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Pharmaceuticals's current Gross Margin % of 80.26% is 32.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Citius Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Pharmaceuticals's current Gross Margin % is 80.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (CTXR) has a current Gross Margin % of 80.26%. The current Gross Margin % is 80.26% and 32.2% above the Biotechnology industry median of 60.69. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Citius Pharmaceuticals (CTXR), the current Gross Margin % is 80.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score
Get the complete analysis for CTXR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTXR has been successfully added to your 
